Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
5 Top Stocks With Great Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next release.
Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
3 Reasons Why Vertex (VRTX) Is a Great Growth Stock
by Zacks Equity Research
Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.
Looking for a Growth Stock? Why It is Time to Focus on Vertex (VRTX)
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).
Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.
Surging Earnings Estimates Signal Good News for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
What's in Store for Vertex in 2020 After a Remarkable 2019?
by Kinjel Shah
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.
Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
by Zacks Equity Research
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
Buy These 5 Stocks With Attractive Sales Growth Right Now
by Swayta Shah
Sales growth is an important metric for any company, as it is a vital part of growth projections and instrumental in strategic decision making.
Momentum ETFs & Stocks to Buy on Renewed Market Rally
by Sweta Killa
Momentum investing would be a winning strategy for those seeking higher returns in a short spell. This is because the strategy seeks to capitalize on the continuance of an existing market trend.
3 Reasons Growth Investors Will Love Vertex (VRTX)
by Zacks Equity Research
Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.
Why Vertex (VRTX) Might be Well Poised for a Surge
by Zacks Equity Research
Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
by Zacks Equity Research
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Buy this Cloud-Based Business Services Stock After Earnings on Strong Growth?
by Benjamin Rains
ServiceNow posted stronger-than-projected Q4 2019 results on January 29. Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast-growing, cloud-focused business services firm...
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.